Hutchmed (China) Limited (HCM) ORD USD0.10
No change
- Add to watchlist
- Create an alert
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Hutchmed enrols last patient in phase three lung cancer trial
5 November 2025 14:22
(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment for its global phase three 'Saffron' trial evaluating the combination of Orpathys and...
-
Hutchmed takes wraps off expanding oncology pipeline
3 November 2025 12:00
(Sharecast News) - Hutchmed unveiled new details on its expanding oncology pipeline and research strategy, including the launch of its next-generation antibody-targeted therapy conjugate (ATTC) platform,...
-
Hutchmed upbeat on preclinical data for novel cancer therapy
23 October 2025 11:28
(Sharecast News) - Hutchmed China reported preclinical data on Thurdsay, showing strong anti-tumour activity for its novel cancer therapy HMPL-A251, the first investigational drug to emerge from the...
-
Hutchmed to present new and updated clinical data
5 September 2025 09:45
(Sharecast News) - Hutchmed China said on Friday that new and updated clinical data from several of its drug candidates would be presented at two major oncology meetings this month, including the World...
-
Hutchmed enrols last patient in phase 3 lung cancer trial
20 August 2025 09:16
(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment in its phase three 'Sanovo' trial in China testing a combination of 'Orpathys',...
-
Hutchmed to get milestone payment after China drug approval
30 June 2025 12:29
(Sharecast News) - Hutchmed announced on Monday that China's National Medical Products Administration (NMPA) has approved the new drug application for the combination of 'Orpathys'. Or...
-
Hutchmed new drug application accepted in China
5 June 2025 11:18
(Sharecast News) - Hutchmed China and Innovent Biologics announced on Thursday that China's National Medical Products Administration had accepted a new drug application for a combination therapy using...
-
Hutchmed China upbeat on results from lung cancer trial
2 June 2025 10:04
(Sharecast News) - Hutchmed China reported positive interim results from its phase three 'SACHI' trial on Monday, showing that the combination of savolitinib and osimertinib significantly improved...
-
Hutchmed enrols patients for phase two savolitinib trial
22 April 2025 08:46
(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for the registration phase of its phase two clinical trial, evaluating savolitinib in Chinese patients with...
-
Hutchmed renal cell carcinoma trial meets primary endpoint
19 March 2025 10:55
(Sharecast News) - Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial evaluating the combination of fruquintinib and sintilimab as a...
-
Hutchmed announces progress, hits milestone with lung cancer treatment
2 January 2025 15:30
(Sharecast News) - Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment and a substantial divestment aimed at bolstering its core...
-
Hutchmed to receive $10m milestone payment from partner Takeda
13 December 2024 09:36
(Sharecast News) - Hutchmed China announced on Friday that it would receive a $10m milestone payment from its partner Takeda, following a national reimbursement recommendation for 'Fruzaqla', or...
Company announcements Announcements
-
Enrollment Complete in SAFFRON Global Phase III
5 November 2025 07:00
HUTCHMED (China) Limited
-
Updates from R&D Event
3 November 2025 07:00
HUTCHMED (China) Limited
-
HUTCHMED Presents Data at AACR NCI EORTC
23 October 2025 07:00
HUTCHMED (China) Limited
-
Vesting of awards under Long Term Incentive Plan
21 October 2025 09:30
HUTCHMED (China) Limited
-
Appointment of Independent Non-executive Director
14 October 2025 09:30
HUTCHMED (China) Limited
-
Data to be Presented at the 2025 ESMO Congress
13 October 2025 07:05
HUTCHMED (China) Limited
-
HUTCHMED Highlights Data to be Presented at ESMO
2 October 2025 07:00
HUTCHMED (China) Limited
-
Total Voting Rights
30 September 2025 09:30
HUTCHMED (China) Limited
-
HUTCHMED to Present R&D Updates on October 31 2025
12 September 2025 07:00
HUTCHMED (China) Limited
-
HUTCHMED Highlights Data to be Presented at CSCO
5 September 2025 07:00
HUTCHMED (China) Limited
-
Directorate Change
26 August 2025 07:00
HUTCHMED (China) Limited
-
HUTCHMED Completes Enrollment of Phase III Trial
20 August 2025 07:00
HUTCHMED (China) Limited
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.